P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions.
about
Multiscale systems biology and physics of thrombosis under flow.Microfluidics and coagulation biologyIn microfluidico: Recreating in vivo hemodynamics using miniaturized devicesRGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injuryMultiscale prediction of patient-specific platelet function under flowMultiscale simulation of thrombus growth and vessel occlusion triggered by collagen/tissue factor using a data-driven model of combinatorial platelet signalling.Development of a method to quantify platelet adhesion and aggregation under static conditionsMicrofluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirinThe P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assaysAntiplatelet agents can promote two-peaked thrombin generation in platelet rich plasma: mechanism and possible applications.Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.Relipidated tissue factor linked to collagen surfaces potentiates platelet adhesion and fibrin formation in a microfluidic model of vessel injury.Mechanobiology of platelets: techniques to study the role of fluid flow and platelet retraction forces at the micro- and nano-scale.Platelet-targeting thiol reduction sensor detects thiol isomerase activity on activated platelets in mouse and human blood under flowFXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flowMicrofluidic assessment of functional culture-derived platelets in human thrombi under flow.Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.Microfluidic whole blood testing of platelet response to pharmacological agents.Blood clots are rapidly assembled hemodynamic sensors: flow arrest triggers intraluminal thrombus contractionEx vivo recapitulation of trauma-induced coagulopathy and preliminary assessment of trauma patient platelet function under flow using microfluidic technologyShock releases bile acid inducing platelet inhibition and fibrinolysisSystems Analysis of Thrombus Formation.Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis.Systems biology of platelet-vessel wall interactions.Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay.Microfluidic assay of hemophilic blood clotting: distinct deficits in platelet and fibrin deposition at low factor levels.Tissue factor activity under flow.Analysis of platelet function: role of microfluidics and nanodevices.Monitoring in vitro thrombus formation with novel microfluidic devices.Transport physics and biorheology in the setting of hemostasis and thrombosis.Hemodynamic studies of platelet thrombosis using microfluidics.Functional assay of antiplatelet drugs based on margination of platelets in flowing bloodComputational Study of Thrombus Formation and Clotting Factor Effects under Venous Flow Conditions.Minimum wound size for clotting: flowing blood coagulates on a single collagen fiber presenting tissue factor and von Willebrand factor.Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay.Dynamics of Thrombin Generation and Flux from Clots during Whole Human Blood Flow over Collagen/Tissue Factor Surfaces.PlaCor PRT measurement of shear-activated platelet aggregate formation in stable patients treated with single and dual antiplatelet therapy.Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition.
P2860
Q27025541-7EE5BF70-97C4-4098-8FC1-8BDF31A02F69Q27026691-5E7B0617-DB41-4F2D-AE57-4E008BFF6AE6Q28084800-9BDFEA91-AE54-49CB-8A05-A63EEC35EAE5Q30498047-422205B2-9303-4C97-A49D-639E75E6D33AQ30519534-8C491062-5D4E-4A01-B591-3EBEE8E86391Q31133306-1CC29327-8DDB-427B-9457-E7F0496AA981Q33678453-284A151C-FEE7-4C08-90E0-5A57AD2FFE18Q33992761-9E9908E0-519F-43C8-A14C-C39AA92D9217Q34510681-1FDF3C79-99D0-45D1-8183-94C721641630Q34565109-738B955E-4A7E-4D0B-AC72-5A3DCF20F295Q34584420-D2DC2433-1E9A-4F5A-A50A-4D54EDB2DA42Q35130686-EAE4BBC6-30DA-48CC-B0D0-1991FBEBE1A5Q35536278-9FFC2D97-6DF2-49D6-9EEB-C3F8EB80B1B4Q35669517-FAAC0C4C-F4A0-43D5-81DA-C53C0ECE8050Q35883546-CE8C63EF-C3A3-4215-973C-46D695C81F3BQ36070475-5B9D5357-8650-42FE-BC6E-51A58E4DAD7BQ36119331-F731A705-5183-4F90-800D-1A7536DE31DFQ36163331-795ED456-5AA4-4EF1-AB7F-CC8F5D28077FQ36253661-B0B25C9F-8182-48CE-BF87-BAF928946C0DQ36652389-A21536A3-9FD2-4CD0-814B-2388484B6FADQ36807483-E10145CE-37DF-43F7-97AE-DEAE89EBC39BQ36818589-845FF4FE-B138-47E2-B665-02C796070CA6Q36855652-723609D0-162A-4D29-B85D-81AB5E19D925Q37012522-792984D2-8E5B-44F0-B522-5005C763CE08Q37118524-8F96F6D6-325A-4DB0-9F88-1ABD51C264EAQ37599126-0F0A9B90-D7F5-490E-A308-4BC402CE8FC7Q37626553-6749B0C1-9415-44F7-8337-1998C8647AEEQ37691034-711DA54C-4F71-4EF3-9CAB-326C110AA4BBQ37949602-647BCF2C-439F-4A46-B90D-E6C2B62779B1Q38032883-A650399A-1282-4F1F-BF35-06943F756D4BQ38723930-81E2F1FC-4F19-43FE-A4BE-A073208FE72EQ39359352-325A25C3-AB33-4A01-8229-84334BB065EFQ39800614-99CEF36D-7B77-4486-B4D8-19F950118B90Q39817818-28CE0242-5BEB-4296-B41E-A0C13D7880ECQ42365902-7D67706D-3A00-426F-AFB5-90F6DAF6164DQ42551076-920DCD45-854F-41D3-8C0E-AF21EE3596F6Q42725749-3B8C8BF3-0C79-4F31-9234-FFCCE302502CQ43703488-9B8FD004-2C16-44A2-9207-311C00F1A705Q45867421-8F97E56C-3F16-4D32-A4D8-545F6B823E63Q45869349-D24B20D2-2FE4-4944-98CD-3AD563A3A645
P2860
P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
P2Y12 or P2Y1 inhibitors reduc ...... fficacy under flow conditions.
@ast
P2Y12 or P2Y1 inhibitors reduc ...... fficacy under flow conditions.
@en
type
label
P2Y12 or P2Y1 inhibitors reduc ...... fficacy under flow conditions.
@ast
P2Y12 or P2Y1 inhibitors reduc ...... fficacy under flow conditions.
@en
prefLabel
P2Y12 or P2Y1 inhibitors reduc ...... fficacy under flow conditions.
@ast
P2Y12 or P2Y1 inhibitors reduc ...... fficacy under flow conditions.
@en
P2093
P2860
P356
P1433
P1476
P2Y12 or P2Y1 inhibitors reduc ...... fficacy under flow conditions.
@en
P2093
Lawrence F Brass
S F Maloney
S L Diamond
P2860
P304
P356
10.1039/B919728A
P577
2010-01-05T00:00:00Z